The claudin 18.2 targeted therapy market size has grown exponentially in recent years. It will grow from $1.29 billion in 2024 to $1.6 billion in 2025 at a compound annual growth rate (CAGR) of 23.9%. The growth during the historic period was driven by increasing research and development activities, growing government and institutional support, rising incidence of pancreatic cancer, higher healthcare investments in oncology, and expanding global access to targeted therapies.
The claudin 18.2 targeted therapy market size is expected to see exponential growth in the next few years. It will grow to $3.73 billion in 2029 at a compound annual growth rate (CAGR) of 23.6%. The growth during the forecast period is fueled by rising approvals of Claudin 18.2 targeted therapies, increasing prevalence of gastric and gastroesophageal junction cancers, an expanding pipeline of Claudin 18.2 directed therapies, growing interest from pharmaceutical companies, and rising adoption of personalized medicine. The primary trends in the forecast period include technological advancements in monoclonal antibody development, innovations in bispecific antibody therapies, progress in antibody-drug conjugates, investment in biomarker discovery and validation, and research and development in combination therapies.
The growing incidence of gastrointestinal cancers is expected to drive the expansion of the claudin 18.2 targeted therapy market. Gastrointestinal (GI) cancers are malignant tumors that can develop anywhere in the digestive tract, from the esophagus to the rectum. The increase in GI cancers is largely attributed to unhealthy diets that are high in processed foods and low in fiber, which promote inflammation in the gut and elevate the risk of cancer. Claudin 18.2 targeted therapy works by specifically targeting the Claudin 18.2 protein, which is overexpressed in cancer cells. This allows drugs or antibodies to selectively kill cancer cells while leaving healthy tissue unharmed, improving the effectiveness of treatment. According to a July 2025 report from the National Library of Medicine, in 2022, GI cancers accounted for 4,783,391 new cases and 3,235,719 deaths, representing 23.9% of all new cancer cases and 33.2% of cancer-related deaths worldwide. As a result, the rising number of gastrointestinal cancer cases is driving the growth of the claudin 18.2 targeted therapy market.
Leading companies in the claudin 18.2 targeted therapy market are focusing on developing advanced solutions, such as monoclonal antibodies, that target claudin 18.2-expressing cancer cells to improve treatment outcomes. Monoclonal antibodies are lab-engineered proteins designed to bind to specific targets, such as proteins found on the surface of cancer cells, helping the immune system recognize and attack these cells. In March 2024, Astellas Pharma Inc., a pharmaceutical company based in Japan, received approval from Japan's Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab), a treatment for patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on cancer cells, activating the immune system to destroy them. Clinical trials demonstrated that when combined with chemotherapy, it significantly improves progression-free and overall survival compared to chemotherapy alone. This novel therapy provides an effective new treatment option for patients with HER2-negative, CLDN18.2-positive tumors, addressing a significant unmet need in aggressive gastric cancer.
In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to advance its cell therapy strategy by enhancing its pipeline with Gracell's innovative CAR-T therapies, which target blood cancers and autoimmune diseases. AstraZeneca plans to leverage Gracell’s FasTCAR platform to improve treatment effectiveness and manufacturing efficiency. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company based in China, also offers claudin 18.2 targeted therapy.
Major players in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2024. The regions covered in claudin 18.2 targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the claudin 18.2 targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
Claudin 18.2 targeted therapy is an advanced precision cancer treatment designed to selectively target the Claudin 18.2 protein, which is abnormally overexpressed on the surface of certain tumor cells. This therapy specifically attacks cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues.
The primary therapy types of Claudin 18.2 targeted therapy are monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are laboratory-engineered molecules that bind to specific proteins on cancer cells, enabling the immune system to target and destroy them. These therapies are primarily indicated for gastric cancer, pancreatic cancer, esophageal cancer, and others, and are administered via intravenous, oral, and other routes. Key end users include hospitals, oncology centers, research institutes, and others.
The claudin 18.2 targeted therapy market research report is one of a series of new reports that provides claudin 18.2 targeted therapy market statistics, including claudin 18.2 targeted therapy industry global market size, regional shares, competitors with a claudin 18.2 targeted therapy market share, detailed claudin 18.2 targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the claudin 18.2 targeted therapy industry. This claudin 18.2 targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The claudin 18.2 targeted therapy market consists of sales of zolbetuximab, CMG901, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The claudin 18.2 targeted therapy market size is expected to see exponential growth in the next few years. It will grow to $3.73 billion in 2029 at a compound annual growth rate (CAGR) of 23.6%. The growth during the forecast period is fueled by rising approvals of Claudin 18.2 targeted therapies, increasing prevalence of gastric and gastroesophageal junction cancers, an expanding pipeline of Claudin 18.2 directed therapies, growing interest from pharmaceutical companies, and rising adoption of personalized medicine. The primary trends in the forecast period include technological advancements in monoclonal antibody development, innovations in bispecific antibody therapies, progress in antibody-drug conjugates, investment in biomarker discovery and validation, and research and development in combination therapies.
The growing incidence of gastrointestinal cancers is expected to drive the expansion of the claudin 18.2 targeted therapy market. Gastrointestinal (GI) cancers are malignant tumors that can develop anywhere in the digestive tract, from the esophagus to the rectum. The increase in GI cancers is largely attributed to unhealthy diets that are high in processed foods and low in fiber, which promote inflammation in the gut and elevate the risk of cancer. Claudin 18.2 targeted therapy works by specifically targeting the Claudin 18.2 protein, which is overexpressed in cancer cells. This allows drugs or antibodies to selectively kill cancer cells while leaving healthy tissue unharmed, improving the effectiveness of treatment. According to a July 2025 report from the National Library of Medicine, in 2022, GI cancers accounted for 4,783,391 new cases and 3,235,719 deaths, representing 23.9% of all new cancer cases and 33.2% of cancer-related deaths worldwide. As a result, the rising number of gastrointestinal cancer cases is driving the growth of the claudin 18.2 targeted therapy market.
Leading companies in the claudin 18.2 targeted therapy market are focusing on developing advanced solutions, such as monoclonal antibodies, that target claudin 18.2-expressing cancer cells to improve treatment outcomes. Monoclonal antibodies are lab-engineered proteins designed to bind to specific targets, such as proteins found on the surface of cancer cells, helping the immune system recognize and attack these cells. In March 2024, Astellas Pharma Inc., a pharmaceutical company based in Japan, received approval from Japan's Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab), a treatment for patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on cancer cells, activating the immune system to destroy them. Clinical trials demonstrated that when combined with chemotherapy, it significantly improves progression-free and overall survival compared to chemotherapy alone. This novel therapy provides an effective new treatment option for patients with HER2-negative, CLDN18.2-positive tumors, addressing a significant unmet need in aggressive gastric cancer.
In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to advance its cell therapy strategy by enhancing its pipeline with Gracell's innovative CAR-T therapies, which target blood cancers and autoimmune diseases. AstraZeneca plans to leverage Gracell’s FasTCAR platform to improve treatment effectiveness and manufacturing efficiency. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company based in China, also offers claudin 18.2 targeted therapy.
Major players in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2024. The regions covered in claudin 18.2 targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the claudin 18.2 targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
Claudin 18.2 targeted therapy is an advanced precision cancer treatment designed to selectively target the Claudin 18.2 protein, which is abnormally overexpressed on the surface of certain tumor cells. This therapy specifically attacks cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues.
The primary therapy types of Claudin 18.2 targeted therapy are monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are laboratory-engineered molecules that bind to specific proteins on cancer cells, enabling the immune system to target and destroy them. These therapies are primarily indicated for gastric cancer, pancreatic cancer, esophageal cancer, and others, and are administered via intravenous, oral, and other routes. Key end users include hospitals, oncology centers, research institutes, and others.
The claudin 18.2 targeted therapy market research report is one of a series of new reports that provides claudin 18.2 targeted therapy market statistics, including claudin 18.2 targeted therapy industry global market size, regional shares, competitors with a claudin 18.2 targeted therapy market share, detailed claudin 18.2 targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the claudin 18.2 targeted therapy industry. This claudin 18.2 targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The claudin 18.2 targeted therapy market consists of sales of zolbetuximab, CMG901, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Claudin 18.2 Targeted Therapy Market Characteristics3. Claudin 18.2 Targeted Therapy Market Trends and Strategies32. Global Claudin 18.2 Targeted Therapy Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Claudin 18.2 Targeted Therapy Market34. Recent Developments in the Claudin 18.2 Targeted Therapy Market
4. Claudin 18.2 Targeted Therapy Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, and Covid and Recovery on the Market
5. Global Claudin 18.2 Targeted Therapy Growth Analysis and Strategic Analysis Framework
6. Claudin 18.2 Targeted Therapy Market Segmentation
7. Claudin 18.2 Targeted Therapy Market Regional and Country Analysis
8. Asia-Pacific Claudin 18.2 Targeted Therapy Market
9. China Claudin 18.2 Targeted Therapy Market
10. India Claudin 18.2 Targeted Therapy Market
11. Japan Claudin 18.2 Targeted Therapy Market
12. Australia Claudin 18.2 Targeted Therapy Market
13. Indonesia Claudin 18.2 Targeted Therapy Market
14. South Korea Claudin 18.2 Targeted Therapy Market
15. Western Europe Claudin 18.2 Targeted Therapy Market
16. UK Claudin 18.2 Targeted Therapy Market
17. Germany Claudin 18.2 Targeted Therapy Market
18. France Claudin 18.2 Targeted Therapy Market
19. Italy Claudin 18.2 Targeted Therapy Market
20. Spain Claudin 18.2 Targeted Therapy Market
21. Eastern Europe Claudin 18.2 Targeted Therapy Market
22. Russia Claudin 18.2 Targeted Therapy Market
23. North America Claudin 18.2 Targeted Therapy Market
24. USA Claudin 18.2 Targeted Therapy Market
25. Canada Claudin 18.2 Targeted Therapy Market
26. South America Claudin 18.2 Targeted Therapy Market
27. Brazil Claudin 18.2 Targeted Therapy Market
28. Middle East Claudin 18.2 Targeted Therapy Market
29. Africa Claudin 18.2 Targeted Therapy Market
30. Claudin 18.2 Targeted Therapy Market Competitive Landscape and Company Profiles
31. Claudin 18.2 Targeted Therapy Market Other Major and Innovative Companies
35. Claudin 18.2 Targeted Therapy Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Claudin 18.2 Targeted Therapy Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on claudin 18.2 targeted therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for claudin 18.2 targeted therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The claudin 18.2 targeted therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:
1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Antibody-Drug Conjugates; Other Therapy Types2) By Indication: Gastric Cancer; Pancreatic Cancer; Esophageal Cancer; Other Indications
3) By Route Of Administration: Intravenous; Oral; Other Route Of Administrations
4) By End-User: Hospitals; Oncology Centers; Research Institutes; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies; Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates; Dna Damaging Agent-Based Antibody-Drug Conjugates; Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy; Vaccines; Small Molecule Inhibitors
Companies Mentioned: Bristol Myers Squibb Company; Amgen Inc.; Astellas Pharma Inc.; Jiangsu Hengrui Medicine Co. Ltd.; Shanghai Henlius Biotech Inc.; Legend Biotech Corporation; Zai Lab Limited; Harbour Biomed Ltd.; CARsgen Therapeutics Holdings Limited; Genor Biopharma Co. Ltd.; Phanes Therapeutics Inc.; Suzhou Zelgen Biopharmaceuticals Co. Ltd.; Triumvira Immunologics Inc.; SOTIO Biotech a.s.; Leap Therapeutics; Allogene Therapeutics; AskGene Pharma Inc.; Elpiscience Biopharmaceutical Co. Ltd.; I-Mab Biopharma Co. Ltd.; Antegene Biopharma Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The companies featured in this Claudin 18.2 Targeted Therapy market report include:- Bristol Myers Squibb Company
- Amgen Inc.
- Astellas Pharma Inc.
- Jiangsu Hengrui Medicine Co. Ltd.
- Shanghai Henlius Biotech Inc.
- Legend Biotech Corporation
- Zai Lab Limited
- Harbour Biomed Ltd.
- CARsgen Therapeutics Holdings Limited
- Genor Biopharma Co. Ltd.
- Phanes Therapeutics Inc.
- Suzhou Zelgen Biopharmaceuticals Co. Ltd.
- Triumvira Immunologics Inc.
- SOTIO Biotech a.s.
- Leap Therapeutics
- Allogene Therapeutics
- AskGene Pharma Inc.
- Elpiscience Biopharmaceutical Co. Ltd.
- I-Mab Biopharma Co. Ltd.
- Antegene Biopharma Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | October 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 1.6 Billion |
| Forecasted Market Value ( USD | $ 3.73 Billion |
| Compound Annual Growth Rate | 23.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
